



February 1, 2021

Case #: WA 163032

Via Electronic Mail

Michael A. Russin, CEO
Nexgen Pharmaceuticals, LLC
953 Hilltop Drive, Suite 100
Weatherford, Texas 76086-8812

Mr. Russin:

We are enclosing copies of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Absolute Veterinary Compounding Pharmacy, 2005 Fort Worth Hwy, #100, Weatherford, Texas, by the U.S. Food and Drug Administration (FDA) during May 31, 2017 through June 2, 2017 and June 5 – 6, 2017. When the Agency concludes that an inspection is “closed” under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Rebecca Asente, Compliance Officer, at 504-846-6104 or rebecca.asente@fda.hhs.gov.

Sincerely,

Digitally signed by John W. Diehl - S4
DN: c=US, o=L.S. Government, ou=HHS
ou=FDA, ou=People, cn=John W. Diehl -
S4
0.9.2342.19200300.100.1.1=2000099727
Date: 2021.02.01 15:34:18 -0600

John W. Diehl, M.S
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

U.S. Food & Drug Administration
Office of Pharmaceutical Quality Operations, Division II
4040 N. Central Expressway, Suite 300
Dallas, Texas 75204
www.fda.gov